41. Orr SJ, Morgan NM, Buick RJ, Boyd CR, Elliott J, et al. (2007) SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J Biol Chem 282: 3418–3422. 42. Frobose H, Ronn SG, Heding PE, Mendoza H, Cohen P, et al. (2006) Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol 20: 1587–1596. 43. Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, et al. (2006) Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 7: 148–155. 44. Tannahill GM, Elliott J, Barry AC, Hibbert L, Cacalano NA, et al. (2005) SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 25: 9115–9126. 45. Hamerman JA, Tchao NK, Lowell CA, Lanier LL (2005) Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 6: 579–586. 46. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G (2007) TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131: 1124–1136. SOCS2 and DC Maturation 47. An H, Hou J, Zhou J, Zhao W, Xu H, et al. (2008) Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 9: 542–550. 48. An H, Zhao W, Hou J, Zhang Y, Xie Y, et al. (2006) SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 25: 919–928. 49. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR (2002) Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22: 7802–7811. 50. Naka T, Fujimoto M, Tsutsui H, Yoshimura A (2005) Negative regulation of cytokine and TLR signalings by SOCS and others. Adv Immunol 87: 61–122. 51. Machado FS, Esper L, Dias A, Madan R, Gu Y, et al. (2008) Native and aspirin- triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. J Exp Med 205: 1077–1086. PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e7178